| Name | Title | Contact Details |
|---|---|---|
Raegan McClain |
Vice President and Chief Ethics, Compliance and Risk Management Officer | Profile |
Barry Rosenfeld |
Senior Director, Corporate Counsel | Profile |
Barry Rosenfeld |
Senior Vice President and General Counsel | Profile |
Jill Andersen |
General Counsel and Chief Compliance Officer | Profile |
Jill Andersen |
General Counsel, Corporate Secretary and Chief Compliance Officer | Profile |
Dey Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
ProUroCare is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.
Its never easy to admit that you or someone you care about is addicted to alcohol or drugs. But once you recognize the problem, the road to recovery appears at your feet. The first step down that road is to find professional help.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).